【24h】

Autoimmune bullous diseases: ocular manifestations and management.

机译:自身免疫性大疱性疾病:眼部表现和管理。

获取原文
获取原文并翻译 | 示例
           

摘要

The ocular manifestations of autoimmune bullous diseases are common and potentially sight-threatening. Major ophthalmic involvement is most commonly seen in mucous membrane pemphigoid (cicatricial pemphigoid), epidermolysis bullosa acquisita, linear IgA bullous disease, pemphigus vulgaris and paraneoplastic pemphigus. The main pathological process is related to autoimmune-induced conjunctival inflammation with consequent lid and corneal pathology, which may eventually result in permanent visual loss. Ocular involvement can be asymptomatic. Early detection is aided by careful attention to symptoms and signs of early ophthalmic disease. Ocular disease can be difficult to treat and management usually involves systemic therapy with immunomodulators to control inflammation and prevent progression to irreversible blindness, as well as surgical intervention in advanced disease. Recent advances in treatment, including methotrexate, mycophenolate mofetil, monoclonal antibodies and topical tacrolimus therapies, have led to promising results.
机译:自身免疫性大疱性疾病的眼部表现很常见,并且可能威胁视力。主要的眼部受累最常见于粘膜天疱疮(瘢痕性天疱疮),表皮松解性大疱性天疱疮,线性IgA大疱性疾病,寻常性天疱疮和副肿瘤性天疱疮。主要病理过程与自身免疫性结膜炎相关,并伴有眼睑和角膜病理,最终可能导致永久性视力丧失。眼部受累可能是无症状的。仔细注意早期眼科疾病的症状和体征有助于早期发现。眼部疾病可能难以治疗,治疗通常涉及使用免疫调节剂进行全身治疗以控制炎症并防止进展为不可逆转的失明,以及对晚期疾病进行手术干预。最近的治疗进展包括甲氨蝶呤,霉酚酸酯,单克隆抗体和他克莫司局部疗法,已取得了可喜的结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号